Importantly, clinical evaluation of an anti-TNF therapy in multiple sclerosis (MS) failed (6, 7) and anti-TNF therapy of juvenile rheumatoid arthritis resulted in development of MS-like exacerbations and demyelinating lesions in some patients (8). The gene discussed is TNF; the disease is myeloid sarcoma.